Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Appl Physiol Nutr Metab ; 49(2): 213-222, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-37820387

ABSTRACT

We have studied the effects of individual and combined treatment of insulin (I) and naringin (NAR) on the bone structure and biomechanical properties of femurs from streptozotocin (STZ)-induced diabetic rats. Male Wistar rats were divided into five groups: (1) controls, (2) STZ-induced diabetic rats, (3) STZ-induced diabetic rats treated with I, (4) STZ-induced diabetic rats treated with NAR, and (5) STZ-induced diabetic rats treated with I + NAR. Bone mineral density (BMD), bone histomorphometry, biomechanical testing, and bone biomarker expressions were accomplished in femur of all animals, as well as serum biochemical analyses. The combined treatment of I + NAR increased the body weight and the femur BMD from STZ-induced diabetic rats. The bone biomechanical properties and the bone morphology of the femurs from STZ-induced diabetic rats were also improved by the combined treatment. The increased number of osteoclasts in STZ-induced diabetic rats was partially prevented by I, NAR, or I + NAR. NAR or I + NAR completely blocked the decrease in the number of osteocalcin (+) cells in the femur from STZ-induced diabetic rats. RUNX family transcription factor 2 immunostaining was much lower in STZ-induced diabetic rats than in control animals; the combination of I + NAR totally blocked this effect. The combined treatment not only ameliorated bone quality and function, but also normalized the variables related to glucose metabolism. Therefore, the combination of I + NAR might be a better therapeutic strategy than the individual I or NAR administration to reduce bone complications in diabetic patients.


Subject(s)
Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 1 , Flavanones , Humans , Rats , Male , Animals , Diabetes Mellitus, Type 1/complications , Insulin , Rats, Wistar , Diabetes Mellitus, Experimental/complications , Bone Density
2.
Curr Med Chem ; 29(16): 2913-2936, 2022.
Article in English | MEDLINE | ID: mdl-34547992

ABSTRACT

BACKGROUND: Osteoporosis is the most common skeletal disorder worldwide. Flavonoids have the potential to alleviate bone alterations in osteoporotic patients with the advantage of being safer and less expensive than conventional therapies. OBJECTIVE: The main objective is to analyze the molecular mechanisms triggered in bone by different subclasses of flavonoids. In addition, this review provides an up-to-date overview of the cellular and molecular aspects of osteoporotic bones versus healthy bones, and a brief description of some epidemiological studies indicating that flavonoids could be useful for osteoporosis treatment. METHODS: The PubMed database was searched in 2001- 2021 using the keywords osteoporosis, flavonoids, and their subclasses such as flavones, flavonols, flavanols, isoflavones, flavanones and anthocyanins, focusing the data on the molecular mechanisms triggered in bone. RESULTS: Although flavonoids comprise many compounds that differ in structure, their effects on bone loss in postmenopausal women or in ovariectomized-induced osteoporotic animals are quite similar. Most of them increase bone mineral density and bone strength, which occur through an enhancement of osteoblastogenesis and osteoclast apoptosis, a decrease in osteoclastogenesis, as well as an increase in neovascularization on the site of the osteoporotic fracture. CONCLUSION: Several molecules of signaling pathways are involved in the effect of flavonoids on osteoporotic bone. Whether all flavonoids have a common mechanism or they act as ligands of estrogen receptors remains to be established. More clinical trials are necessary to know better their safety, efficacy, delivery and bioavailability in humans, as well as comparative studies with conventional therapies.


Subject(s)
Flavones , Osteoporosis , Animals , Anthocyanins/therapeutic use , Female , Flavones/therapeutic use , Flavonoids/pharmacology , Flavonoids/therapeutic use , Flavonols/therapeutic use , Humans , Osteoporosis/drug therapy , Osteoporosis/prevention & control
3.
Anticancer Agents Med Chem ; 22(13): 2411-2418, 2022.
Article in English | MEDLINE | ID: mdl-34875993

ABSTRACT

BACKGROUND: Colon cancer is one of the most important causes of death in the entire world. New pharmacological strategies are always needed, especially in resistant variants of this pathology. We have previously reported that drugs such as menadione (MEN), D, L-buthionine-S,R-sulfoximine or calcitriol, used in combination, enhanced cell sensibility of breast and colon tumour models, due to their ability to modify the oxidative status of the cells. Melatonin (MEL), a hormone regulating circadian rhythms, has anti-oxidant and anti-apoptotic properties at low concentrations, while at high doses, it has been shown to inhibit cancer cell growth. OBJECTIVE: The objective of this study is to determine the antitumoral action of the combination MEN and MEL on colon cancer cells. METHODS: Caco-2 cells were employed to evaluate the effects of both compounds, used alone or combined, on cellular growth/morphology, oxidative and nitrosative stress, and cell migration. RESULTS: MEN plus MEL dramatically reduced cell proliferation in a time and dose-dependent manner. The antiproliferative effects began at 48 h. At the same time, the combination modified the content of superoxide anion, induced the formation of reactive nitrogen species and enhanced catalase activity. Cell migration process was delayed. Also, changes in nuclear morphology consistent with cell death were observed. CONCLUSION: The enhanced effect of simultaneous use of MEN and MEL on Caco-2 cells suggests that this combined action may have therapeutic potential as an adjuvant on intestinal cancer acting in different oncogenic pathways.


Subject(s)
Colonic Neoplasms , Melatonin , Antioxidants/metabolism , Antioxidants/pharmacology , Buthionine Sulfoximine/pharmacology , Caco-2 Cells , Colonic Neoplasms/drug therapy , Humans , Melatonin/pharmacology , Oxidative Stress , Vitamin K 3/pharmacology
4.
Actual. osteol ; 18(1): 40-52, 2022. ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1396075

ABSTRACT

El "microbioma" no solo está constituido por los microbios, sino por todos los componen-tes que viven en el mismo hábitat conforman-do un nicho ecológico. Es decir, está conformado por los microorganismos (bacterias, hongos, protozoos, etc.), todo el espectro de moléculas producidas por ellos tales como sus componentes estructurales (ácidos nucleicos, proteínas, lípidos y glúcidos), meta-bolitos, toxinas, etc., y las moléculas producidas por el huésped. El microbioma intestinal (MI) ha emergido como un factor que tiene un gran efecto sobre la cantidad, calidad y fuerza del hueso. Las investigaciones revelan que la homeostasis ósea está ligada al micro-bioma saludable, mientras que la disbiosis (alteración en la biodiversidad microbiana) puede exacerbar la actividad osteoclástica y promover la osteoporosis. Los mecanismos potenciales involucrados en la interacción del microbioma intestinal y el hueso son la influencia del metabolismo del huésped, el mantenimiento de la integridad intestinal y regulación de la absorción de nutrientes, la regulación del eje intestino-sistema inmune y la modulación del sistema endocrino. Es decir que hay múltiples vías por las cuales el MI influye sobre el hueso, pero estos y otros mecanismos deben profundizarse más aún. También es necesario que se identifiquen y caractericen mejor los microorganismos que están asociados a las enfermedades óseas. El conocimiento de estos aspectos podría ser útil para el desarrollo de herramientas terapéuticas basadas en el MI que puedan mejorar la eficacia de los distintos tratamientos existentes. (AU)


The microbiome is not only constituted by microbes, but by all the components that live in the same habitat forming an ecological niche. It is conformed by the microorganisms ( bacteria, fungi, protozoa, etc), the entire spectrum of molecules produced by them (nucleic acids, proteins, lipid and carbohydrates, metabolites, toxins, etc) and the molecules produced by the host. The intestinal microbiome (IM) has emerged as a factor with great effects on the quantity, quality and strength of bone. The investigations reveal that bone homeostasis is linked to the healthy microbiome, while the dysbiosis (alteration in the microbial biodiversity) can exacerbate the osteoclastic activity and promote osteoporosis. The potential mechanisms involved in the interaction between IM and bone are the influence of the host metabolism, the maintenance of the intestinal integrity and regulation of the nutrient absorption, the regulation of the intestine/ immune system axis and the modulation of the endocrine system. That is, there are multiple ways through which IM influences on bone, but these and other mechanisms need to be further studied. It is also necessary to identify and characterize the microorganisms associated with the bone diseases. Knowledge of these aspects could be useful to develop therapeutical tools based on the IM that could improve the efficacy of the current treatments. (AU)


Subject(s)
Humans , Osteoblasts/immunology , Osteoclasts/immunology , Bone and Bones/immunology , Dysbiosis/complications , Gastrointestinal Microbiome/immunology , Osteoblasts/metabolism , Osteoclasts/metabolism , Bone and Bones/metabolism , Intestines/immunology , Intestines/microbiology
5.
Can J Physiol Pharmacol ; 98(8): 548-556, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32762631

ABSTRACT

The aim of this study was to determine new insights into the molecular mechanisms involved in the antiproliferative action of menadione + calcitriol (MEN+D) on MCF-7 cells. After 24 h, MEN+D inhibited the cell growth but was not observed with each single treatment. The combined drugs reduced the mitochondrial respiration at that time, as judged by an increase in the proton leak and a decrease in the ATP generation and coupling efficiency. At longer times, 48 or 96 h, either D or MEN reduced the proliferation, but the effect was higher when both drugs were used together. The combined treatment increased the superoxide anion ([Formula: see text]) and nitric oxide (NO•) contents as well as acidic vesicular organelles (AVOs) formation. The percentage of cells showing the lower mitochondrial membrane potential (ΔΨm) was highly increased by the combined therapy. LC3-II protein expression was enhanced by any treatment. In conclusion, the antiproliferative action of MEN+D involves oxidative/nitrosative stress, mitochondrial alteration, and autophagy. This combined therapy could be useful to treat breast cancer cells because it inhibits multiple oncogenic pathways more effectively than each single agent.


Subject(s)
Autophagy/drug effects , Breast Neoplasms/pathology , Calcitriol/pharmacology , Mitochondria/drug effects , Nitrosative Stress/drug effects , Oxidative Stress/drug effects , Vitamin K 3/pharmacology , Antineoplastic Agents/pharmacology , Cell Cycle/drug effects , Cell Proliferation/drug effects , Cell Respiration/drug effects , Drug Synergism , Humans , MCF-7 Cells , Membrane Potential, Mitochondrial/drug effects , Mitochondria/metabolism , Mitochondria/pathology
6.
Cancer Chemother Pharmacol ; 86(1): 1-13, 2020 07.
Article in English | MEDLINE | ID: mdl-32572519

ABSTRACT

Cancer constitutes a group of heterogeneous diseases that share common features. They involve the existence of altered cellular pathways which result in uncontrolled cell proliferation. Deregulation of production and/or elimination of reactive oxygen species (ROS) appear to be a relevant issue in most of them. ROS have a dual role in cell metabolism: they are compromised in normal cellular homeostasis, but their overproduction has been reported to promote oxidative stress (OS), a process that may induce the damage of cell structures. ROS accumulation is implicated in the activation of signaling pathways that promote cell proliferation and metabolic adaptations to tumour growth. One characteristic of cancer cells is the sensitivity to OS, which often results from the combination of high anabolic needs and hypoxic growth conditions. However, there is still no clear evidence about the levels of oxidant species that promote cellular transformation or, otherwise, if OS induction could be adequate as an antitumour therapeutic tool. There is a need for novel therapeutic strategies based on the new knowledge of cancer biology. Targeting oncogenic molecular mechanisms with non-classical agents and/or natural compounds would be beneficial as chemoprevention or new adjuvant therapies. In addition, epigenetics and environment, and particularly dietary factors may influence the development and prevention of cancer. This article will present a revision of the current research about molecular aspects proposed to be involved in the anticancer features of oxidant and antioxidant-based therapies targeting cancer cells, and their participation in the balance of oxidative species and cancer cell death.


Subject(s)
Antineoplastic Agents/pharmacology , Neoplasms/drug therapy , Neoplasms/prevention & control , Reactive Oxygen Species/metabolism , Animals , Anticarcinogenic Agents/pharmacology , Antioxidants/metabolism , Antioxidants/pharmacology , Clinical Trials as Topic , Enzymes/metabolism , Flavonoids/pharmacology , Glutathione/metabolism , Humans , Molecular Targeted Therapy , Neoplasms/metabolism , Oxidative Stress , Vitamins/metabolism , Vitamins/pharmacology
7.
J Neurotrauma ; 37(3): 528-533, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31354034

ABSTRACT

Inhibition of dendritic cell maturation and activation, together with abnormal functioning of cell-mediated immunity, has been reported in chronic spinal cord injury (SCI). The development of immune-based therapies could: 1) prevent or slow down limit further tissue damage in chronic SCI, and 2) promote tissue regeneration. To identify novel candidate molecular pathways mediating SCI-induced immune changes, we performed whole-genome microarray and molecular pathway analyses. Subjects with motor complete chronic SCI (> 2 years post-injury) and uninjured controls were selected from an ongoing study. Microarray analysis was performed with RNA extracted from circulating monocytes. Partek Genomic Suite (PGS) software was used to limit the 54,000 gene list to only those genes up-regulated or down-regulated by 2-fold or more in SCI compared with control. Pathway analyses were performed with Ingenuity Systems IPA software to identify biological pathways of interest involving differentially expressed genes. Genes of interest were then confirmed by quantitative PCR (qPCR). Six SCI subjects and five uninjured controls were included in the final analyses. A molecular pathway related to immune cell trafficking was identified as being significantly upregulated in the SCI subjects. Two genes in that network, transmembrane domain protein (TMEM)176A and TMEM176B, were notable for the magnitude of overexpression. Dendritic cells have been shown to mediate recovery and/or protective autoimmunity in central nervous system injuries and have the capacity to induce neuroprotection and neurogenesis in stroke patients. High TMEM176A and TMEM176B levels have been shown to prevent dendritic cell maturation and inhibit dendritic cell activity in the general population. Here, we report overexpression of both genes in SCI compared with control subjects. Thus, we propose that TMEM176A and TMEM176B are candidate genes involved in inhibiting protective immune responses in SCI. This study may support future research aimed at developing new targets for therapies to promote immune system-mediated neuroprotection and recovery in SCI.


Subject(s)
Dendritic Cells/physiology , Gene Expression Profiling/methods , Genetic Association Studies/methods , Membrane Proteins/genetics , Spinal Cord Injuries/genetics , Adult , Aged , Chronic Disease , Humans , Male , Membrane Proteins/biosynthesis , Middle Aged , Spinal Cord Injuries/diagnosis , Spinal Cord Injuries/metabolism
8.
J Cell Biochem ; 121(4): 2927-2937, 2020 04.
Article in English | MEDLINE | ID: mdl-31692073

ABSTRACT

Bone resorption and organelle homeostasis in osteoclasts require specialized intracellular trafficking. Sorting nexin 10 (Snx10) is a member of the sorting nexin family of proteins that plays crucial roles in cargo sorting in the endosomal pathway by its binding to phosphoinositide(3)phosphate (PI3P) localized in early endosomes. We and others have shown previously that the gene encoding sorting Snx10 is required for osteoclast morphogenesis and function, as osteoclasts from humans and mice lacking functional Snx10 are dysfunctional. To better understand the role and mechanisms by which Snx10 regulates vesicular transport, the aim of the present work was to study PIKfyve, another PI3P-binding protein, which phosphorylates PI3P to PI(3,5)P2. PI(3,5)P2 is known to be required for endosome/lysosome maturation, and the inhibition of PIKfyve causes endosome enlargement. Overexpression of Snx10 also induces accumulation of early endosomes suggesting that both Snx10 and PIKfyve are required for normal endosome/lysosome transition. Apilimod is a small molecule with specific, nanomolar inhibitory activity on PIKfyve but only in the presence of key osteoclast factors CLCN7, OSTM1, and Snx10. This observation suggests that apilimod's inhibitory effects are mediated by endosome/lysosome disruption. Here we show that both Snx10 and PIKfyve colocalize to early endosomes in osteoclasts and coimmunoprecipitate in vesicle fractions. Treatment with 10 nM apilimod or genetic deletion of PIKfyve in cells resulted in the accumulation of early endosomes, and in the inhibition of osteoclast differentiation, lysosome formation, and secretion of TRAP from differentiated osteoclasts. Snx10 and PIKfyve also colocalized in gastric zymogenic cells, another cell type impacted by Snx10 mutations. Apilimod-specific inhibition of PIKfyve required Snx10 expression, as it did not inhibit lysosome biogenesis in Snx10-deficient osteoclasts. These findings suggest that Snx10 and PIKfyve are involved in the regulation of endosome/lysosome homeostasis via the synthesis of PI(3,5)P2 and may point to a new strategy to prevent bone loss.


Subject(s)
Lysosomes/metabolism , Osteoclasts/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Sorting Nexins/metabolism , Animals , Biological Transport , Bone Resorption/metabolism , Cytoplasm/metabolism , Endosomes/metabolism , Gene Expression Regulation , Hydrazones/pharmacology , Mice , Morpholines/pharmacology , Phosphorylation , Pyrimidines/pharmacology , RAW 264.7 Cells
9.
Biomed Pharmacother ; 94: 21-26, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28750356

ABSTRACT

BACKGROUND: Calcitriol (D) or 1,25(OH)2D3 inhibits the growth of several tumor cells including breast cancer cells, by activating cell death pathways. Menadione (MEN), a glutathione-depleting compound, may be used to potentiate the antiproliferative actions of D on cancer cells. We have previously shown in vitro that MEN improved D-induced growth arrest on breast cancer cell lines, inducing oxidative stress and DNA damage via ROS generation. Treatment with MEN+D resulted more effective than D or MEN alone. OBJECTIVE: To study the in vivo effect of calcitriol, MEN or their combination on the development of murine transplantable triple negative breast tumor M-406 in its syngeneic host. METHODS: Tumor M-406 was inoculated s.c., and when tumors reached the desired size, animals were randomly assigned to one of four groups receiving daily i.p. injections of either sterile saline solution (controls, C), MEN, D, or both (MEN+D). Body weight and tumor volume were recorded three times a week. Serum calcium was determined before and at the end of the treatment, at which time tumor samples were obtained for histological examination. RESULTS: None of the drugs, alone or in combination, affected mice body weight in the period studied. The combined treatment reduced tumor growth rate (C vs. MEN+D, P<0.05) and the corresponding histological sections exhibited small remaining areas of viable tumor only in the periphery. A concomitant DNA fragmentation was observed in all treated groups and MEN potentiated the calcitriol effect on tumor growth. CONCLUSIONS: As previously observed in vitro, treatment with MEN and D delayed tumor growth in vivo more efficiently than the individual drugs, with evident signals of apoptosis induction. Our results propose an alternative protocol to treat triple negative breast cancer, using GSH depleting drugs together with calcitriol, which would allow lower doses of the steroid to maintain the antitumor effect while diminishing its adverse pharmacological effects.


Subject(s)
Calcitriol/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Vitamin K 3/therapeutic use , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Calcitriol/pharmacology , Calcium/blood , Cell Nucleus/drug effects , Cell Nucleus/metabolism , DNA Fragmentation/drug effects , Female , Mice , Mitosis/drug effects , Triple Negative Breast Neoplasms/blood , Triple Negative Breast Neoplasms/pathology , Tumor Burden/drug effects , Vitamin K 3/pharmacology
10.
J Pediatr Endocrinol Metab ; 27(11-12): 1161-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25026125

ABSTRACT

Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency need glucocorticoid (GC) therapy, which alters bone mineral metabolism. We analyze clinical and biochemical parameters and different polymorphisms of candidate genes associated with bone mineral density (BMD) in CAH patients. The CAH patients treated with GC and healthy controls were studied. Anthropometric parameters, biochemical markers of bone turnover, and BMD were evaluated. Polymerase chain reaction technique was used to genotype different candidate genes. The 192-192 genotype frequency (IGF-I) was lower in poorly controlled patients than that from controls. In CAH patients, FF genotype (vitamin D receptor, VDR) correlated with lower lumbar spine BMD and there was a significant association between the 0-0 genotype (IGF-I) and high values of ß-CrossLaps and a low total BMD. This study contributes to understanding of the association of genetic determinants of BMD with the variable response to GC treatment in CAH patients and demonstrates the usefulness of these genetic polymorphisms.


Subject(s)
Adrenal Hyperplasia, Congenital/metabolism , Adrenal Hyperplasia, Congenital/pathology , Bone Density , Insulin-Like Growth Factor I/genetics , Polymorphism, Genetic/genetics , Receptors, Calcitriol/genetics , Adolescent , Adrenal Hyperplasia, Congenital/drug therapy , Adrenal Hyperplasia, Congenital/genetics , Adult , Case-Control Studies , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , Hormone Replacement Therapy , Humans , Male , Prognosis , Steroid 21-Hydroxylase/metabolism , Young Adult
11.
Anticancer Drugs ; 25(7): 810-8, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24681551

ABSTRACT

The prognosis and incidence of colon cancer are linked to vitamin D3 serum levels. To evaluate the effects of D,L-buthionine-S,R-sulfoximine (BSO), 1,25(OH)2D3 and their combination on intestinal Caco-2 cell growth, to elucidate the possible cellular mechanisms involved in their antiproliferative action, and to determine whether BSO acts as a sensitizer to 1,25(OH)2D3 treatment, enabling minimization of the toxic effects caused by high doses of the steroid. Human colon cancer Caco-2 cells were treated with 1,25(OH)2D3, BSO, both, or vehicle. Cell proliferation was evaluated by crystal violet staining. Cell cycle and mitochondrial membrane potential were measured by flow cytometry. Total glutathione, catalase, superoxide dismutase, superoxide anion levels, and alkaline phosphatase activities were analyzed by spectrophotometry. DNA fragmentation was evaluated using the terminal dUTP nick end labeling assay. BSO and 1,25(OH)2D3 inhibited Caco-2 cell growth, an effect that was higher with the combined treatment. The antiproliferative effect produced by the combination could be protected by ascorbic acid. BSO plus 1,25(OH)2D3 induced cell cycle arrest and suppressed cell division. Total glutathione decreased and superoxide anion increased with BSO and BSO plus 1,25(OH)2D3. Catalase activity increased with the combined treatment. Mitochondrial membrane potential and alkaline phosphatase activity were altered by 1,25(OH)2D3 alone or plus BSO. The percentage of terminal dUTP nick end labeling-positive cells was increased. BSO increases the antiproliferative effect of 1,25(OH)2D3 on Caco-2 cells through induction of oxidative stress, which occurs simultaneously with DNA breakage. The antioxidant system can partially compensate the damage induced by BSO plus 1,25(OH)2D3. Cell differentiation induction is also involved in the response to the combined treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Buthionine Sulfoximine/pharmacology , Calcitriol/pharmacology , Cell Cycle Checkpoints/drug effects , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Oxidative Stress/drug effects , Alkaline Phosphatase/metabolism , Caco-2 Cells , DNA Fragmentation/drug effects , Drug Synergism , Humans , Membrane Potential, Mitochondrial/drug effects
12.
Cancer Invest ; 30(8): 604-14, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22963190

ABSTRACT

Environment may influence the development and prevention of cancer. Calcitriol has been associated with calcium homeostasis regulation. Many epidemiological, biochemical, and genetic studies have shown non-classic effects of vitamin D, such as its involvement in the progression of different cancers. Although vitamin D induces cellular arrest, triggers apoptotic pathways, inhibits angiogenesis, and alters cellular adhesion, the precise mechanisms of its action are still not completely established. This article will present a revision about the molecular aspects proposed to be involved in the anticancer action of calcitriol. Adequate levels of vitamin D to prevent cancer development will also be discussed.


Subject(s)
Antineoplastic Agents/metabolism , Neoplasms/genetics , Neoplasms/metabolism , Vitamin D/metabolism , Animals , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Calcitriol/metabolism , Calcitriol/pharmacology , Calcium Signaling/drug effects , Cell Adhesion Molecules/metabolism , Cell Cycle/drug effects , Cell Differentiation/drug effects , Humans , Neoplasms/prevention & control , Neovascularization, Physiologic/drug effects , Polymorphism, Genetic , Reactive Oxygen Species/metabolism , Receptors, Calcitriol/genetics , Vitamin D/pharmacology
13.
Cancer Invest ; 30(8): 560-70, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22931489

ABSTRACT

Calcitriol or 1,25(OH)(2)D(3) is a negative growth regulator of breast cancer cells. The aim of this study was to determine whether L-buthionine-S,R-sulfoximine, a glutathione-depleting drug, modifies the antiproliferative effects of 1,25(OH)(2)D(3) on MCF-7 cells. For comparison, we included studies in MCF-7 cells selected for vitamin D resistance and in human mammary epithelial cells transformed with SV40 and ras. Our data indicate that L-buthionine-S,R-sulfoximine enhances the growth inhibition of 1,25(OH)(2)D(3) in all transformed breast cell lines. This effect is mediated by ROS leading to apoptosis. In conclusion, BSO alters redox state and sensitizes breast cancer cells to 1,25(OH)(2)D(3)-mediated apoptosis.


Subject(s)
Apoptosis/drug effects , Breast Neoplasms/metabolism , Buthionine Sulfoximine/pharmacology , Reactive Oxygen Species/metabolism , Vitamin D/analogs & derivatives , Caspases/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Enzyme Activation/drug effects , Female , Humans , Oxidation-Reduction/drug effects , Vitamin D/pharmacology
14.
J Pediatr Endocrinol Metab ; 24(7-8): 511-7, 2011.
Article in English | MEDLINE | ID: mdl-21932590

ABSTRACT

Clinical, biochemical and genetic analysis related to bone mineral density (BMD) were carried out in children born small for gestational age (SGA) that failed to achieve postnatal catch-up growth (CUG), SGA children that completed CUG and adequate for gestational age (AGA) children. Serum IGF-I, IGF-II, IGF binding protein-3 and acid-labile subunit were lower in the SGA-CUG children as compared with the other groups. Frequencies of polymorphic variants of vitamin D receptor, estrogen receptor and collagen genes were similar among groups. The genotype 194-192 of the IGF-I gene was higher in the SGA-CUG and 196-192 was higher in the SGA+CUG group. In the SGA-CUG group, the genotype SS of the COLIA1 gene was associated with lower BMD. Therefore, IGF system and COLIA1 polymorphism distinguish prepubertal SGA-CUG children from the SGA+CUG children of the same age. Furthermore, COLIA1 polymorphism could be useful to predict osteopenia in SGA-CUG children.


Subject(s)
Bone Density , Bone Diseases, Metabolic/diagnosis , Bone Diseases, Metabolic/genetics , Child Development , Growth Disorders/blood , Growth Disorders/genetics , Infant, Small for Gestational Age , Polymorphism, Genetic , Bone Diseases, Metabolic/etiology , Carrier Proteins/blood , Child , Child, Preschool , Collagen Type I/genetics , Collagen Type I, alpha 1 Chain , Early Diagnosis , Female , Genetic Association Studies , Glycoproteins/blood , Growth Disorders/physiopathology , Humans , Infant, Newborn , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor II/analysis , Male
15.
Arch Biochem Biophys ; 509(2): 191-6, 2011 May 15.
Article in English | MEDLINE | ID: mdl-21458410

ABSTRACT

The role of 1,25(OH)(2)D(3) on the intestinal NCX activity was studied in vitamin D-deficient chicks (-D) as well as the hormone effect on NCX1 protein and gene expression and the potential molecular mechanisms underlying the responses. Normal, -D and -D chicks treated with cholecalciferol or 1,25(OH)(2)D(3) were employed. In some experiments, -D chicks were injected with cycloheximide or with cycloheximide and 1,25(OH)(2)D(3) simultaneously. NCX activity was decreased by -D diet, returning to normal values after 50 IU daily of cholecalciferol/10 days or a dose of 1µg calcitriol/kg of b.w. for 15 h. Cycloheximide blocked NCX activity enhancement produced by 1,25(OH)(2)D(3). NCX1 protein and gene expression were diminished by -D diet and enhanced by 1,25(OH)(2)D(3). Vitamin D receptor expression was decreased by -D diet, effect that disappeared after 1,25(OH)(2)D(3) treatment. Rapid effects of 1,25(OH)(2)D(3) on intestinal NCX activity were also demonstrated. The abolition of the rapid effects through addition of Rp-cAMPS and staurosporine suggests that non genomic effects of 1,25(OH)(2)D(3) on NCX activity are mediated by activation of PKA and PKC pathways. In conclusion, 1,25(OH)(2)D(3) enhances the intestinal NCX activity in -D chicks through genomic and non genomic mechanisms.


Subject(s)
Calcitriol/pharmacology , Calcium Channel Agonists/pharmacology , Gene Expression Regulation/drug effects , Sodium-Calcium Exchanger/metabolism , Vitamin D Deficiency/metabolism , Vitamins/pharmacology , Animals , Calcitriol/therapeutic use , Calcium Channel Agonists/therapeutic use , Chickens , Cyclic AMP-Dependent Protein Kinases/metabolism , Intestinal Mucosa/metabolism , Intestines/drug effects , Protein Kinase C/metabolism , Signal Transduction/drug effects , Vitamin D/metabolism , Vitamin D Deficiency/drug therapy , Vitamins/therapeutic use
16.
J Pediatr Endocrinol Metab ; 23(5): 463-71, 2010 May.
Article in English | MEDLINE | ID: mdl-20662345

ABSTRACT

Children born small for gestational age (SGA) are prone to developing obesity, insulin resistance and type 2 diabetes. Adiponectin and leptin are adipocytokines associated with insulin sensitivity parameters. We aimed to relate serum adiponectin and leptin levels with insulin sensitivity parameters in prepuberal SGA children with and without catch-up growth (SGA+CUG; SGA-CUG, respectively) and to analyze the usefulness of these adipocytokines as early markers of insulin resistance. We analysed adiponectin, proinsulin, leptin, growth factors, insulin, HOMA IR and HOMA beta(cell) in 23 SGA+CUG, 26 SGA-CUG children compared with 48 prepuberal appropiate for gestational age (AGA). SGA children had adiponectin levels comparable to AGA children. Leptin levels were different between sexes, showed to be higher in SGA+CUG group (p=0.040) and these were significantly correlated with insulin sensitivity parameters. These results suggest leptin resistance as an adaptive mechanism to increase energy balance, but an altered functional response of adipocytes cannot be discarded.


Subject(s)
Adiponectin/blood , Infant, Small for Gestational Age/blood , Insulin Resistance/physiology , Leptin/blood , Puberty/blood , Blood Glucose/analysis , Child , Female , Homeostasis , Humans , Infant, Newborn , Infant, Small for Gestational Age/growth & development , Insulin/blood , Intercellular Signaling Peptides and Proteins/blood , Male , Proinsulin/blood , Puberty/physiology
17.
J Steroid Biochem Mol Biol ; 113(3-5): 227-32, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19429426

ABSTRACT

Calcitriol or 1,25(OH)(2)D(3) is a negative growth regulator of MCF-7 breast cancer cells. The growth arrest is due to apoptosis activation, which involves mitochondrial disruption. This effect is blunted in vitamin D resistant cells (MCF-7(DRes) cells). Menadione (MEN), a glutathione (GSH)-depleting compound, may potentiate antitumoral effects of anticancer drugs. The aim of this study was to investigate whether MEN enhances cellular responsiveness of MCF-7 cells to 1,25(OH)(2)D(3). Cells were cultured and treated with different concentrations of 1,25(OH)(2)D(3)+/-MEN or vehicle for 96 h. GSH levels and the activity of antioxidant enzymes were determined by spectrophotometry and ROS production by flow cytometry. Both drugs decreased growth and enhanced ROS in MCF-7 cells, obtaining the maximal effects when 1,25(OH)(2)D(3) was combined with MEN (P<0.01 vs. Control and vs. each compound alone). MCF-7(DRes) cells were not responsive to 1,25(OH)(2)D(3), but the cell proliferation was slightly inhibited by the combined treatment. Calcitriol and MEN separately enhanced antioxidant enzyme activities, but when they were used in combination, the effect was more pronounced (P<0.05 vs. Control and vs. each compound alone). MEN, calcitriol and the combined treatment decreased GSH levels (P<0.05 vs. Control). The data indicate that MEN potentiates the effect of 1,25(OH)(2)D(3) on growth arrest in MCF-7 cells by oxidative stress and increases the activities of antioxidant enzymes, probably as a compensatory mechanism.


Subject(s)
Breast Neoplasms/drug therapy , Calcitriol , Cell Line, Tumor/drug effects , Vitamin K 3 , Vitamins , Animals , Antioxidants/metabolism , Calcitriol/pharmacology , Calcitriol/therapeutic use , Cell Line, Tumor/cytology , Cell Shape/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Female , Humans , Oxidative Stress , Reactive Oxygen Species/metabolism , Vitamin K 3/pharmacology , Vitamin K 3/therapeutic use , Vitamins/pharmacology , Vitamins/therapeutic use
18.
Actual. osteol ; 4(3): 121-127, sept.-dic. 2008.
Article in Spanish | LILACS | ID: lil-614286

ABSTRACT

El cáncer es una de las mayores causas de muerte en el mundo. Si bien la vitamina D (colecalciferol) ha sido asociada a la regulación de la homeostasis de calcio, muchos son los datos epidemiológicos, bioquímicos y genéticos sobre otros efectos importantes de la vitamina D, como el desarrollo y la progresión de diferentes cánceres. El objetivo del presente artículo es revisar distintos aspectos acerca de los mecanismos de acción y efectos moleculares de la vitamina D o sus metabolitos y de los indicadores epidemiológicos que los correlacionan con el cáncer, su prevención y tratamiento. El estudio de los efectos de la vitamina D se ha vuelto muy amplio: nuevos genes, nuevos blancos, mecanismos diferentes. Niveles adecuados de vitamina D son necesarios para una gran cantidad de procesos fisiológicos y no solamente para el mantenimiento de la homeostasis del calcio. Los estudios clínicos podrían revisar las recomendaciones sobre las dosis de vitamina D que puedan proteger también contra el desarrollo del cáncer.


Subject(s)
Humans , Male , Female , Calcitriol/metabolism , Calcitriol/therapeutic use , Vitamin D Deficiency/complications , Vitamin D Deficiency/epidemiology , Neoplasms/prevention & control , Vitamin D , Vitamin D/metabolism , Vitamin D/chemistry , Cell Differentiation , Nutritional Status
19.
Digestion ; 77(1): 22-34, 2008.
Article in English | MEDLINE | ID: mdl-18277073

ABSTRACT

An overview of current information on the mechanisms by which intestinal calcium absorption occurs is described in this article. Both paracellular and transcellular pathways are analyzed. Special emphasis focuses on molecules participating in the latter pathway, such as TRPV5 and TRPV6 channels, located in the apical region of the enterocytes, CB(9k) and CB(28k), presumably involved in the cation movement from the apical to the basolateral pole of the cell, and PMCA(1b) and Na(+)/Ca(2+) exchanger, proteins that extrude Ca(2+) from the cells. Current concepts on the relative importance of paracellular and transcellular calcium transport and the vitamin D dependence of each pathway are referred and analyzed showing the contrasting views on this issue. More detailed information is given regarding the stimulatory effect of vitamin D on intestinal Ca(2+) absorption either in animal models or in the human intestine. The possible mechanisms triggered by hormones such as PTH, calcitonin, estrogen, thyroid hormone, glucocorticoids and different nutritional factors on intestinal calcium absorption are also reviewed. Finally, the influence of physiological conditions such as growth, pregnancy, lactation and aging on intestinal calcium absorption are discussed.


Subject(s)
Calcium/metabolism , Intestinal Absorption/physiology , Intestinal Mucosa/metabolism , Animals , Calcitriol/physiology , Calcium Signaling , Hormones/physiology , Humans
20.
Article in Spanish | MEDLINE | ID: mdl-20803935

ABSTRACT

The effects of the environment, particularly dietary factors, may influence in the development and prevention of cancer. Vitamin D (colecalciferol) has been associated for years with calcium homeostasis regulation, but many epidemiological, biochemical and genetic studies reveal non classic effects of vitamin D, such as vitamin D involvement in the progression of different types of cancer. The aim of the present article was to give a review about the molecular mechanisms of the antineoplasic action of vitamin D. These effects are still not completely established, but it is well known that vitamin D induces cellular arrest, triggers apoptotic pathways, inhibits angiogenesis and alters cellular adhesion. To maintain suitable vitamin D levels seems to be necessary for many physiological processes, and not only for bone homeostasis. Clinical studies might determine vitamin D levels that can also protect against the cancer development.


Subject(s)
Antineoplastic Agents/therapeutic use , Calcitriol/therapeutic use , Neoplasms/prevention & control , Vitamin D/therapeutic use , Calcitriol/physiology , Cell Proliferation/drug effects , Humans , Vitamin D/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...